Patent · US Active

Anti-Siglec-7 antibodies having reduced effector function

US11912766B2 · kind B2 · utility

0Cited by
2References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 11, 2019
Grant dateFeb 27, 2024
Priority date—
Expiry dateFeb 24, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies that have reduced effector function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.